PriceTargets.com logo

Fennec Pharmaceuticals - FENC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 88.68 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$6.36 As of 08/19/2022 01:00 AM ET
▼ -0.1 (-1.55%)

This chart shows the closing price for FENC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fennec Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FENC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FENC

Analyst Price Target is $12.00
▲ +88.68% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Fennec Pharmaceuticals in the last 3 months. The average price target is $12.00, with a high forecast of $14.00 and a low forecast of $10.00. The average price target represents a 88.68% upside from the last price of $6.36.

This chart shows the closing price for FENC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Fennec Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/26/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/24/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/20/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/20/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/8/2022Craig HallumReiterated RatingBuy$14.00Low
4/27/2022WedbushReiterated RatingOutperformLow
12/1/2021Maxim GroupLower TargetBuy$12.00 ➝ $10.00High
11/30/2021Cantor FitzgeraldDowngradeOverweight ➝ NeutralHigh
11/30/2021Craig HallumLower TargetBuy$19.00 ➝ $14.00High
6/24/2021HC WainwrightReiterated RatingBuyHigh
6/3/2021HC WainwrightLower TargetBuy$15.00 ➝ $14.00Medium
5/28/2021Maxim GroupReiterated RatingBuy$12.00N/A
4/21/2021Craig HallumInitiated CoverageBuy$17.00High
4/19/2021Maxim GroupInitiated CoverageBuy$12.00Low
3/17/2021WedbushReiterated RatingOutperformHigh
8/12/2020WedbushLower TargetHold ➝ Outperform$18.00 ➝ $11.00High
6/23/2020WedbushReiterated RatingOutperform$18.00Low
6/4/2020Cantor FitzgeraldInitiated CoverageOverweight$18.00High
5/15/2020HC WainwrightReiterated RatingBuy$17.00 ➝ $15.00Medium
4/15/2020HC WainwrightReiterated RatingBuy$17.00High
2/18/2020HC WainwrightReiterated RatingBuy$17.00Low
2/11/2020HC WainwrightReiterated RatingBuy$17.00Low
12/2/2019HC WainwrightReiterated RatingBuy$17.00Medium
5/28/2019HC WainwrightSet TargetBuy$17.00Low
5/10/2019WedbushReiterated RatingOutperform$16.00High
3/14/2019WedbushReiterated RatingOutperform$16.00High
12/21/2018HC WainwrightSet TargetBuy$18.00Low
12/10/2018HC WainwrightReiterated RatingBuy$18.00Low
10/11/2018The Goldman Sachs GroupInitiated CoverageBuyHigh
10/11/2018Dawson JamesInitiated CoverageBuyHigh
9/17/2018WedbushLower TargetOutperform$17.00 ➝ $16.00Low
8/14/2018HC WainwrightSet TargetBuy$18.00Low
8/7/2018HC WainwrightSet TargetBuy$18.00High
6/20/2018HC WainwrightReiterated RatingBuy$18.00Low
5/23/2018HC WainwrightReiterated RatingBuy$18.00High
4/2/2018HC WainwrightReiterated RatingBuy$18.00Low
3/22/2018HC WainwrightReiterated RatingBuy$16.00Medium
3/12/2018WedbushInitiated CoverageOutperform$17.00High
2/20/2018HC WainwrightInitiated CoverageBuy ➝ Buy$16.00Medium
11/29/2017LaidlawInitiated CoverageBuy ➝ Buy$22.00High
(Data available from 8/19/2017 forward)

News Sentiment Rating

0.71 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2022
  • 3 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/22/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/21/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2022

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Fennec Pharmaceuticals logo
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Read More

Today's Range

Now: $6.36
Low: $6.23
High: $6.61

50 Day Range

MA: $6.32
Low: $5.31
High: $7.08

52 Week Range

Now: $6.36
Low: $3.40
High: $7.59

Volume

46,918 shs

Average Volume

39,965 shs

Market Capitalization

$165.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.09

Frequently Asked Questions

What sell-side analysts currently cover shares of Fennec Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Fennec Pharmaceuticals in the last year: Cantor Fitzgerald, Craig Hallum, Maxim Group, and Wedbush.
View the latest analyst ratings for FENC.

What is the current price target for Fennec Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Fennec Pharmaceuticals in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 88.7%. Craig Hallum has the highest price target set, predicting FENC will reach $14.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $10.00 for Fennec Pharmaceuticals in the next year.
View the latest price targets for FENC.

What is the current consensus analyst rating for Fennec Pharmaceuticals?

Fennec Pharmaceuticals currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FENC will outperform the market and that investors should add to their positions of Fennec Pharmaceuticals.
View the latest ratings for FENC.

What other companies compete with Fennec Pharmaceuticals?

Other companies that are similar to Fennec Pharmaceuticals include Talaris Therapeutics, Cellectis, ProKidney, Ikena Oncology and INmune Bio. Learn More about companies similar to Fennec Pharmaceuticals.

How do I contact Fennec Pharmaceuticals' investor relations team?

Fennec Pharmaceuticals' physical mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company's listed phone number is 919-636-4530. The official website for Fennec Pharmaceuticals is www.fennecpharma.com. Learn More about contacing Fennec Pharmaceuticals investor relations.